Matrix metalloproteinases in renal development and disease

Journal of the American Society of Nephrology

Volumn 11, Issue 3, 2000, Pages 574-581

  Lenz, Oliver ^a   Elliot, Sharon J ^a   Stetler Stevenson, William G ^b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

ENZYME ANALYSIS; ENZYME STRUCTURE; HUMAN; KIDNEY DEVELOPMENT; KIDNEY DISEASE; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

EID: 0034006936     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Arthur MJ: Fibrosis and altered matrix degradation. Digestion 59: 376-380, 1998
2. Norman JT, Lewis MP: Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int Suppl 54: S61-S63, 1996
3. Heidland A, Sebekova K, Paczek L, Teschner M, Dammrich J, Gaciong Z: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies. Kidney Int Suppl 62: S32-S35, 1997
4. El Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O: Renal fibrosis: Insights into pathogenesis and treatment. Int J Biochem Cell Biol 29: 55-62, 1997
5. He C, Zalups RK, Henderson DA, Striker GE, Striker LJ: Molecular analysis of spontaneous glomerulosclerosis in Os/+ mice, a model with reduced nephron mass. Am J Physiol 269: F266-F273, 1995
6. Abrass CK, Peterson CV, Raugi GJ: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 37: 1695-1702, 1988
7. Schnaper HW, Robson A: Nephrotic syndrome: Minimal change disease, focal glomerulosclerosis, and related disorders. In: Diseases of the Kidney, 5th Ed., edited by Schrier CW, Gottschalk CW, Boston, Little, Bmwn & Co., 1992, pp 1731-1784
8. Warshaw BL, Edelbrock HH, Ettenger RB, Malekzadeh MH, Pennisi AJ, Uittenbogaart CH, Fine RN: Progression to end-stage renal disease in children with obstructive uropathy. J Pediatr 100: 183-187, 1982
9. Morel-Maroger SL, Killen PD, Chi E, Striker GE: The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 51: 181-192, 1984
10. Thoenes W, Rumpelt HJ: The obsolescent renal glomerulus -collapse, sclerosis, hyalinosis, fibrosis. A light- and electron microscopical study on human biopsies. Virchows Arch A Pathol Anat Histol 377: 1-15, 1977
11. Jeong HJ, Kim YS, Oh CK, Park K, Choi IJ: Immunologic and nonimmunologic contributors to glomerular segmental sclerosis in renal transplantation. Transplant Proc 28: 1224-1225, 1996
12. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154, 1991
13. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148: 1345-1350, 1996
14. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular-cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 56: 944-949, 1996
15. Will H, Hinzmann B: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 231: 602-608, 1995
16. Takino T, Sato H, Yamamoto E, Seiki M: Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 155: 293-298, 1995
17. Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 270: 23013-23020, 1995
18. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994
19. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases: Novel targets for directed cancer therapy. Drugs Aging 11: 229-244, 1997
20. Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkcs SP, Werb Z: Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122: 1723-1736, 1996
21. Brenner CA, Adler RR, Rappolee DA, Pedersen RA, Werb Z: Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev 3: 848-859, 1989
22. Lelongt B, Trugnan G, Murphy G, Ronco PM: Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol 136: 1363-1373, 1997
23. Norman JT, Gatti L, Wilson PD, Lewis M: Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis. Exp Nephrol 3: 88-89, 1995
24. Schaefer L, Man X, August C, Matzkies F, Lorenz T, Schaefer RM: Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. Diabetologia 40: 1035-1043, 1997
25. Jacot TA, Striker GE, Stetler-Stevenson M, Striker LJ: Mesungial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. Lab Invest 75: 791-799, 1996
26. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 378: 151-160, 1997
27. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J 12: 1075-1095, 1998
28. Bode W, Gomis-Ruth FX, Huber R, Zwilling R, Stocker W: Structure of astacin and implications for activation of astacins and zinc-ligation of collagenases. Nature 358: 164-167, 1992
29. Mallya SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedal-Hansen H, Van Wart HE: Characterization of 58-kilo-dalton human neutrophil collagenase: Comparison with human fibroblast collagenase. Biochemistry 29: 10628-10634, 1990
30. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97: 761-768, 1996
31. Hasty KA, Hibbs MS, Kang AH, Mainardi CL: Heterogeneity among human collagenases demonstrated by monoclonal antibody that selectively recognizes and inhibits human neutrophil collagenase. J Exp Med 159: 1455-1463, 1984
32. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: Purification and activation of the precursor and enzymic properties. J Biol Chem 267: 21712-21719, 1992
33. Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H: Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fihrosarcoma cells. Biochem J 285: 603-611, 1992
34. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R: High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem 273: 10672-10681, 1998
35. Borden P, Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Expression 7: 159-178, 1997
36. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, Sato H, Seiki M, Okada Y: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 56: 2707-2710, 1996
37. Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378. 1989
38. Strongin AY, Collier I, Bannikov G, Manner BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase: Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270: 5331-5338, 1995
39. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997
40. Carome MA, Striker LJ, Peten EP, Moore J, Yang CW, Stetler-Stevenson WG, Striker GE: Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol 264: F923-F929, 1993
41. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683-693, 1996
42. Kinoshita T, Sato H, Takino T, Itoh M, Akizawa T, Seiki M: Processing of a precursor of 72-kilodalton type IV collagenase/ gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res 56: 2535-2538, 1996.
43. Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375: 244-247, 1995
44. Turck J, Pollock AS, Lovett DH: Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int 51: 1397-1400, 1997
45. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010, 1998
46. Corcoran ML, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 270: 13453-13459, 1995
47. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277: 225-228, 1997
48. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM. Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422, 1998
49. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H: Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 6: 255-263, 1995
50. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG: Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99: 2470-2478, 1997
51. Singhal PC, Sagar S, Garg P: Simulated glomerular pressure modulates mesangial cell 72 kDa metalloproteinase activity. Connect Tissue Res 33: 257-263, 1996
52. Trachtman H, Futterweit S, Garg P, Reddy K, Singhal PC: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun 218: 704-708, 1996
53. He CJ, Yang CW, Peten EP, Liu ZH, Patel A, Striker LJ, Striker GE: Collagen and collagenase mRNAs in normal and sclerotic glomeruli: Predictors of progression and response to therapy. Kidney Int Suppl 49: S39-S43, 1995
54. Engelmyer E, van Goor H, Edwards DR, Diamond JR: Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. J Am Soc Nephrol 5: 1675-1683, 1995
55. Sharma AK, Mauer SM, Kim Y, Michael AF: Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. J Lab Clin Med 125: 754-761, 1995
56. Diamond JR: Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 26: 133-140, 1995
57. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26: 152-161, 1995
58. Sagar S, Sorbi D, Arbeit LA, Singhal PC: Morphine modulates 72-kDa matrix metalloproteinase. Am J Physiol 267: F654-F659, 1994
59. Duymelinck C, Deng JT, Dauwe SE, De Broe ME, Verpooten GA: Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 54: 804-818, 1998
60. Reckelhoff JF, Baylis C: Glomerular metalloprotease activity in the aging rat kidney: Inverse correlation with injury. J Am Soc Nephrol 3: 1835-1838, 1993
61. The United States Renal Data System: USRDS Annual Data Report, 1995
62. Fumitake Gejyo Collaborate Study Group: The treatment of uraemic diabetic: Are we doing enough? A view from Japan Nephrol Dial Transplant 10: 47-55, 1995
63. Raine AE: A rising tide of diabetic nephropathy: The warning before the flood? Nephrol Dial Transplant 10: 460-461, 1995
64. Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 55: 1-28, 1999
65. Morgensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease: With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32: 64-78, 1983
66. Makino H: Glomerular extracellular matrix in glomerulosclerosis by molecular biology. Nippon Rinsho 50: 3038-3045, 1992
67. Cacnazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G: Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant 12: 443-448, 1997
68. Leehey DJ, Song RH, Alavi N, Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 44: 929-935, 1995
69. McLennan SV, Yue DK, Turtle JR: Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron 79: 293-298, 1998
70. Reckelhoff JF, Tygart VL, Mitias MM, Walcoti JL: STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42: 1425-1432, 1993
71. Reckelhoff JF, Tygart VL, Racusen LC, Dzielak DJ: Glomerular metalloprotease activity in streptozotocin-treated rats and in spontaneously diabetic rats (BB/DP). Life Sci 55: 941-950, 1994
72. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren Physiol Biochem 17: 316-325, 1994
73. Wu K, Setly S, Mauer SM, Killen P, Nagase H, Michael AF, Tsilibary EC: Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anat 158: 155-165, 1997
74. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, Nomoto Y, Sakai H: In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int 52: 111-119, 1997
75. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40: 1449-1454, 1997
76. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ: IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy. Diabetes 40: 1638-1644, 1999
77. Elliot SJ, Striker LJ, Hattori M, Yang CW, He CJ, Peten EP, Striker GE: Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I. Endocrinology 133: 1783-1788, 1993
78. Marti HP, Lee L, Kashgurian M, Lovett DH: Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenasc. Am J Pathol 144: 82-94, 1994
79. Cohen MP, Sharma K, Guo J, Eltayeb BO, Ziyadeh FN: The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. Exp Nephrol 6: 226-233, 1998
80. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139-1146, 1995
81. Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 24: 190-196, 1998
82. Mogyorosi A, Ziyadeh FN: Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose. Am J Physiol 275: F827-F832, 1998
83. Kitamura M, Suto TS: TGF-beta and glomerulonephritis: Anti-inflammatory versus prosclerotic actions. Nephrol Dial Transplant 12: 669-679, 1997
84. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM: Pathogenesis of diabetic nephropathy: A radical approach. Nephrol Dial Transplant 12: 664-668, 1997
85. Mattana J, Margiloff L, Sharma P, Singhal PC: Oxidation of the mesangial matrix metalloproteinase-2 impairs gelatinolytic activity. Inflammation 22: 269-276, 1998
86. Craven PA, DeRubertis FR, Kagan VE, Melhem M, Studer RK: Effects of supplementation with vitamin C or E on albuminuria, glomerular TGF-β. and glomerular size in diabetes. J Am Soc Nephrol 8: 1405-1414, 1997
87. Studer RK, Craven PA, DeRubertis FR: Antioxidant inhibition of protein kinase C signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 46: 918-925, 1997
88. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
89. Schaefer L, Schaefrr RM, Ling H, Teschner M, Heidland A: Renal proteinases and kidney hypertrophy in experimental diabetes. Diabetologia 37: 567-571, 1994
90. Singh AK, Mo W, Dunea G, Arruda JA: Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 9: 802-810, 1998
91. Mott JD, Khalifah RG, Nagase H, Shield CF, Hudson JK, Hudson BG: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 52: 1302-1312, 1997
92. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
93. Lenz O, Zheng F, Vilar J, Doublier S, Lupia E, Schwedler S, Striker LJ, Striker GE: The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. Nephrol Dial Transplant 13: 3074-3078, 1998
94. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489, 1995
95. Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 141: 85-98, 1992
96. Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 9: 397-407, 1998
97. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 97: 1094-1101, 1996
98. Suto TS, Fine LG, Shimizu F, Kitamura M: In vivo transfer of engineered macrophages into the glomerulus: Endogenous TGF-β-mediated defense against macrophage-induced glomerular cell activation. J Immunol 159: 2476-2483, 1997
99. Lefkowith JB: Leukocyte migration in immune complex glomerulonephritis: Rule of adhesion receptors. Kidney Int 51: 1469-1475, 1997
100. Harendza S, Behrens U, Zahner G, Schneider A, Stuhl RA: In vitro characterization of the mesangial phenotype in a proliferative glomerulonephritis of the rat. Nephrol Dial Transplant 12: 2537-2541, 1997
101. Akiyama K, Shikuta K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N, Obata K, Matsui H, Makino H: Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pethol Pharmacol 95: 115-128, 1997
102. Koide H, Nakamura T, Ebihara I, Tomino Y: Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis 28: 32-39, 1996
103. Nakamura T, Fukui M, Ebihara I, Tomino Y, Koide H: Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis. Kidney Int 45: 1593-1605, 1994
104. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78: 629-635, 1998
105. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, Wilks JW: Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1. inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 58: 4001-4007, 1998
106. Senatorski G, Paczek L, Sulowicz W, Gradowska L, Bartlomiejczyk I: Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res Exp Med 198: 199-206, 1998
107. Binder CJ, Weiher H, Exner M, Kerjaschki D: Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 154: 1067-1075, 1999
108. Reuter A. Nestl A, Zwacka RM, Tuckermann J, Waldherr R, Wagner EM, Hoyhtya M, Meyer GA, Angel P, Weiher H: Expression of the recessive glomerulosclerosis gene Mpv17 regulates MMP-2 expression in fibroblasts, the kidney, and the inner ear of mice. Mol Biol Cell 9: 1675-1682, 1998
109. Weiher H, Noda T, Gray DA, Sharpe AH, Jaenisch R: Transgenic mouse model of kidney disease: Insertional inactivation of ubiquitously expressed gene leads to nephrotic syndrome. Cell 62: 425-434, 1990
110. Orellana SA, Avner ED: Cell and molecular biology of kidney development. Semin Nephrol 18: 233-243, 1998
111. Lechner MS, Dressier GR: The molecular basis of embryonic kidney development. Mech Dev 62: 105-120, 1997
112. Dressier GR: Genetic control of kidney development. Adv Nephrol Necker Hosp 26: 1-17, 1997
113. Ganser GL, Stricklin GP, Matrisian LM: EGF and TGF alpha influence in vitro lung development by the induction of matrix-degrading metalloproteinases. Int J Dev Biol 35: 453-461, 1991
114. Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ, Werh Z: Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 125: 681-693, 1994
115. Benaud C, Dickson RB, Thompson EW: Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 50: 97-116, 1998
116. Tanney DC, Feng L, Pollock AS, Lovett DH: Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Dev Dyn 213: 121-129, 1998
117. Ota K, Stetler-Stevenson WG, Yang Q, Kumar A, Wada J, Kashihara N, Wallner EI, Kanwar YS: Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor. Kidney Int 54: 131-142, 1998
118. Kadono Y, Shibahara K, Namiki M, Watanabe Y, Seiki M, Sato H: Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells. Biochem Biophys Res Commun 251: 681-687, 1998
119. Barasch J, Yang J, Qiao J, Tempst P, Erdjument-Bromage H, Leung W, Oliver JA: Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. J Cell Invest 103: 1299-1307, 1999
120. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 272: 22389-22392, 1997
121. Sakurai H, Nigam SK: Transforming growth factor-beta selectively inhibits branching morphogenesis but not tubulogenesis. Am J Physiol 272: F139-F146, 1997
122. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171-175, 1994
123. Brenner BM, Anderson S: The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol 19[Suppl 6]: S1-S7, 1992
124. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 54: 1999-2007, 1998
125. Lucas SR, Costa SV, Miraglia SM, Zaladek GF: Functional and morphometric evaluation of offspring kidney after intrauterine undernutrition. Pediatr Nephrol 11: 719-723, 1997
126. Gilbert T, Cibert C, Moreau E, Geraud G, Merlet-Benichou C: Early defect in branching morphogenesis of the ureteric bud in induced nephron deficit. Kidney Int 50: 783-795, 1996